A Phase 2b randomized, double-blinded, placebo-controlled study in adult patients with moderate-to-severe atopic dermatitis to evaluate multi-dose subcutaneous administration of ANB020

Trial Profile

A Phase 2b randomized, double-blinded, placebo-controlled study in adult patients with moderate-to-severe atopic dermatitis to evaluate multi-dose subcutaneous administration of ANB020

Planning
Phase of Trial: Phase II

Latest Information Update: 11 Oct 2017

At a glance

  • Drugs ANB 020 (Primary)
  • Indications Atopic dermatitis
  • Focus Therapeutic Use
  • Most Recent Events

    • 11 Oct 2017 New trial record
    • 10 Oct 2017 According to an AnaptysBio media release, this trial is expected to begin in the first half of 2018 and data are expected in 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top